CDC presents updated recommendations for meningococcal vaccine in HIV
HIV-infected individuals should receive the meningococcal conjugate vaccine.
(HealthDay News) — In the November fourth issue of the US Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, new recommendations are presented for meningococcal conjugate vaccination among HIV-infected individuals.
Noting that a growing body of evidence suggests increased risk for meningococcal disease in HIV-infected individuals, Jessica R. MacNeil, MPH, from the CDC in Atlanta, and colleagues modified recommendations on vaccination with meningococcal conjugate vaccine.
The authors recommend that all HIV-infected individuals aged ≥2 months should receive meningococcal conjugate vaccine (serogroups A, C, W, and Y); a multi-dose schedule should be used for children aged younger than 2 years. A 2-dose primary series of meningococcal conjugate vaccine is recommended for individuals aged ≥2 years. A booster dose should be given at the earliest opportunity (at least 8 weeks after the previous dose) for persons with HIV who have been previously vaccinated; boosters should continue at appropriate intervals. A booster dose should be administered 3 years later if the most recent dose was received before age 7 years. If the most recent dose was received at age ≥7 years, a booster should be given 5 years later and every 5 years thereafter.
"The recommendations for children aged 2 months through 2 years and persons aged ≥25 years are based on expert opinion; the vaccine was not studied in HIV-infected persons in these age groups," the authors write.
- MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons: Advisory committee on immunization practices, 2016. MMWR. 2016;65(43):1189-1194.